
    
      Part 1 of the study is designed to evaluate the safety and tolerability of a SAD, up to 6
      cohorts,of rolapitant IV (2 mg/mL solution) administered as an IV infusion over 30 minutes.

      In Part 2 of the study, the safety and tolerability of the highest safe and well-tolerated
      dose established in Part 1 will be evaluated in an expanded cohort. The highest safe and
      well-tolerated dose established in Part 1 will be ascertained by the following criteria: an
      upper limit of 90% confidence interval (CI) for Cmax. A minimum of 40 subjects will be
      enrolled in Part 2.
    
  